Active Not Recruiting PHASE3 INTERVENTIONAL 2-arm NCT05524571

Study to Assess Batoclimab in Participants With Active Thyroid Eye Disease

A Phase 3, Multi-center, Randomized, Quadruple-masked, Placebo-controlled Study of Batoclimab for the Treatment of Participants With Active Thyroid Eye Disease (TED)

Sponsor: Immunovant Sciences GmbH

Conditions Thyroid Eye Disease

Interventions Batoclimab Placebo

Updated 22 times since 2022 Last updated: Dec 24, 2025 Started: Jan 5, 2023 Primary completion: Mar 31, 2026 Completion: Mar 31, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05524571, this PHASE3 trial focuses on Thyroid Eye Disease and remains ongoing. Sponsored by Immunovant Sciences GmbH, it has been updated 22 times since 2023, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

22 versions recorded

Jan 2026 — Present [monthly]

Active Not Recruiting PHASE3
Dec 2025 — Jan 2026 [monthly]

Active Not Recruiting PHASE3
Oct 2025 — Dec 2025 [monthly]

Active Not Recruiting PHASE3

Status: Recruiting → Active Not Recruiting
Sep 2025 — Oct 2025 [monthly]

Recruiting PHASE3
May 2025 — Sep 2025 [monthly]

Recruiting PHASE3

▶ Show 17 earlier versions

Jan 2025 — May 2025 [monthly]

Recruiting PHASE3
Sep 2024 — Jan 2025 [monthly]

Recruiting PHASE3
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE3
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE3
May 2024 — Jul 2024 [monthly]

Recruiting PHASE3
Mar 2024 — May 2024 [monthly]

Recruiting PHASE3
Feb 2024 — Mar 2024 [monthly]

Recruiting PHASE3
Jan 2024 — Feb 2024 [monthly]

Recruiting PHASE3
Dec 2023 — Jan 2024 [monthly]

Recruiting PHASE3
Nov 2023 — Dec 2023 [monthly]

Recruiting PHASE3
Oct 2023 — Nov 2023 [monthly]

Recruiting PHASE3
Aug 2023 — Oct 2023 [monthly]

Recruiting PHASE3
Jul 2023 — Aug 2023 [monthly]

Recruiting PHASE3
Jun 2023 — Jul 2023 [monthly]

Recruiting PHASE3
May 2023 — Jun 2023 [monthly]

Recruiting PHASE3
Apr 2023 — May 2023 [monthly]

Recruiting PHASE3

Status: Not Yet Recruiting → Recruiting
Sep 2022 — Apr 2023 [monthly]

Not Yet Recruiting PHASE3

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Immunovant Sciences GmbH

Data source: Immunovant Sciences GmbH

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Adana, Turkey (Türkiye) , Ankara, Turkey (Türkiye) , Barcelona, Spain , Bellaire, United States , Bratislava, Slovakia , Bruges, Belgium , Brussels, Belgium , Budapest, Hungary , Christchurch, New Zealand , Ghent, Belgium and 29 more locations